Peginterferon beta-1a

How it works

It is an immunomodulatory cytokine whose pegylation prolongs its half-life; interferon beta exerts complex effects on immune cell activity and cytokine balance that reduce relapse frequency, though the precise mechanism in MS is not fully understood.

Prescribing in practice

• It can cause hepatic injury and bone-marrow suppression, so liver function and full blood count should be checked before and periodically during treatment.
• Injection-site reactions and flu-like symptoms are common, particularly early on, and may be eased by gradual dose escalation and pre-emptive antipyretics.
• Use with caution where there is a history of depression or seizures, and review for thrombotic microangiopathy or nephrotic syndrome if relevant symptoms arise.

Monitoring

Monitor full blood count, liver function tests, thyroid function and mood, and review for injection-site and systemic reactions during therapy.

Counselling the patient

• Flu-like symptoms are common at first and usually settle; paracetamol or an anti-inflammatory taken around injection time can help.
• Rotate injection sites and report any persistent low mood, jaundice, or unusual bruising.
• Administer it on the same schedule as advised and store it correctly in the fridge.

Evidence & guidelines

The ADVANCE trial demonstrated reduced annualised relapse rates versus placebo, supporting its use as a disease-modifying treatment in relapsing MS.